Vaxxinity Stock Quote VAXX - Stock Price, News, Charts, Message Board, Trades

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Vaxxinity Inc (VAXX) Quote

Vaxxinity Inc (VAXX)

0.1166

-0.0048

(-3.95%)

Closed April 27 4:00PM

Delayed by 15 minutes

0.115

-0.0016

(-1.37%)

After Hours: 7:58PM

Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Current Price

0.115

Bid

0.1051

Ask

0.12

Volume

1,999,747

0.1075 Day's Range 0.125

0.1075 52 Week Range 3.10

Market Cap

Previous Close

0.1214

Open

0.121

Last Trade

Last Trade Time

Financial Volume

$ 234,395

VWAP

0.117212

Average Volume (3m)

734,122

Shares Outstanding

126,745,924

Dividend Yield

-

PE Ratio

-0.27

Earnings Per Share (EPS)

-0.45

Revenue

-

Net Profit

-56.93M

Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particul... Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

vaxxinity.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Vaxxinity Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VAXX. The last closing price for Vaxxinity was $0.12. Over the last year, Vaxxinity shares have traded in a share price range of $ 0.1075 to $ 3.10.

Vaxxinity currently has 126,745,924 shares outstanding. The market capitalization of Vaxxinity is $15.21 million. Vaxxinity has a price to earnings ratio (PE ratio) of -0.27.

Vaxxinity Issues Shareholder Letter

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from...

Form 8-K - Current report

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial...

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.365	-76.0416666667	0.48	0.4818	0.1075	3276495	0.20318355	CS
4	-0.615	-84.2465753425	0.73	0.735	0.1075	1117858	0.27925314	CS
12	-0.585	-83.5714285714	0.7	1.05	0.1075	734122	0.49602214	CS
26	-0.8399	-87.9568541209	0.9549	1.33	0.1075	488932	0.60941364	CS
52	-1.665	-93.5393258427	1.78	3.1	0.1075	347511	1.01713413	CS
156	-16.785	-99.3195266272	16.9	22.77	0.1075	402313	3.78712482	CS
260	-16.785	-99.3195266272	16.9	22.77	0.1075	402313	3.78712482	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M

Tom turtles

Tom turtles 5 days ago

Lol...bye bye VAXX...good riddance

Awl416

Awl416 5 days ago

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Awl416

Awl416 2 months ago

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

81vette

81vette 2 months ago

not off hand,look on fda site,let us know,thanks!!!

Monroe1

Monroe1 2 months ago

Any idea when the Phase 3 trial should finish?

Monksdream

Monksdream 3 months ago

VAXX new 52 week low

Monksdream

Monksdream 6 months ago

Monksdream

Monksdream 7 months ago

VAXX new 52 week low

Monksdream

Monksdream 7 months ago

VAXX new 52 week low

Monksdream

Monksdream 7 months ago

81vette

81vette 1 year ago

new and effective covid booster news coming is the thought,15 days of charting up and institutions loading while crickets are chirping

81vette

81vette 1 year ago

https://ih.advfn.com/stock-market/NASDAQ/vaxxinity-VAXX/stock-news/89692734/vaxxinity-announces-positive-topline-pivotal-phase

81vette

81vette 1 year ago

10Xs ave vol,blowing up scanners on this low float

81vette

81vette 1 year ago

1M short ,squeeze babe !!! could be big news enroute with institutional buying like this

81vette

81vette 1 year ago

biggest ever institution loading> Bank Of America 3.22 mm +3.20 mm +20179.3%
Vanguard 1.53 mm +1.48 mm +2676.7%
Marshall Wace 620.46 k +620.46 k NEW
Element Capital Management 376.89 k +376.89 k NEW
Creative Planning 277.52 k +277.52 k NEW
Renaissance Technologies 262.40 k +262.40 k NEW
Millennium Management 213.62 k +213.62 k NEW
Prime Movers Lab 17.85 mm -179.00 k -1.0%
Two Sigma Investments 128.52 k +128.52 k NEW
Ghisallo Capital Management 100.00 k +100.00 k NEW

81vette

81vette 1 year ago

3Xs ave vol.,no news,dbl bottom,47% insider owned

bandit007

bandit007 2 years ago

Loaded the crap out of this today

bandit007

bandit007 2 years ago

Sexy looking bottom chart. Starting to move up now. $VAXX

bandit007

bandit007 2 years ago

Stop losses below 3 got taken out. Should start moving up now

bandit007

bandit007 2 years ago

Took a few down here

TheFinalCD

TheFinalCD 2 years ago

and on low volume

bandit007

bandit007 2 years ago

bandit007

bandit007 2 years ago

bandit007

bandit007 2 years ago

bandit007

bandit007 2 years ago

I only hold a small position speculating here. Could be either gold or fool’s gold. Could pay off well if it ends up being the real deal. GL

Deano361

Deano361 2 years ago

Trading nicely today now and not spikey

Deano361

Deano361 2 years ago

I'm in this one now. Can't figure out if real or not. Some guy on Twits board claims it's a Nancy Pelosi fraud lol! I have no idea but if they truly figure out a Alz vaccine this will be like Moderna in the 100s

bandit007

bandit007 2 years ago

Nice bounce back from the morning dip. $VAXX

bandit007

bandit007 2 years ago

VAXX hod close?

crudeoil24

crudeoil24 2 years ago

Nice trade! Maybe some news coming next week.

TheFinalCD

TheFinalCD 2 years ago

5.74 vol HALT down

only P1 news

I learned from crude to be careful with P1's I got burned on one that I lost $80,000

#HardLesson

Awl416

Awl416 2 years ago

TheFinalCD

TheFinalCD 2 years ago

crudeoil24

crudeoil24 2 years ago

VAXX halted > Nasdaq circuit breaker.

crudeoil24

crudeoil24 2 years ago

Vaxxinity Shares Surge More Than 40% in Trading Debut After IPO VAXX
12:02 pm ET November 11, 2021 (Dow Jones)

crudeoil24

crudeoil24 2 years ago

Vaxxinity, Inc. is a biotechnology company. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that will improve the access to treatments for a range of indications. Its Vaxxine Platform is designed to connect the immune system to convert the body into its own drug factory, stimulating the production of antibodies with a therapeutic or protective effect. Its technology uses synthetic peptides to mimic and optimally combine biological epitopes in order to selectively activate the immune system, producing antibodies against only the desired targets, including self-antigens, making possible the safe and effective treatment of chronic diseases by vaccines. The modular and synthetic nature of its Vaxxine Platform provides significant in candidate development and has generated multiple product candidates that it is designing for many chronic diseases.

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions